The effect of dapagliflozin on uric acid excretion and serum uric acid level in advanced CKD
Abstract Sodium–glucose cotransporter 2 inhibitors (SGLT2i) exhibit renoprotective effect in patients with chronic kidney disease (CKD) and reduce serum uric acid (UA) in patients with diabetes mellitus. However, it is not clarified whether SGLT2i reduce serum UA levels in patients with advanced CKD...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2023-03-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-023-32072-y |
| _version_ | 1797859971610705920 |
|---|---|
| author | Yukimasa Iwata Shoki Notsu Yushi Kawamura Waka Mitani Shinjiro Tamai Madoka Morimoto Masafumi Yamato |
| author_facet | Yukimasa Iwata Shoki Notsu Yushi Kawamura Waka Mitani Shinjiro Tamai Madoka Morimoto Masafumi Yamato |
| author_sort | Yukimasa Iwata |
| collection | DOAJ |
| description | Abstract Sodium–glucose cotransporter 2 inhibitors (SGLT2i) exhibit renoprotective effect in patients with chronic kidney disease (CKD) and reduce serum uric acid (UA) in patients with diabetes mellitus. However, it is not clarified whether SGLT2i reduce serum UA levels in patients with advanced CKD. This study aimed to investigate the impact of SGLT2i on change in serum UA levels in patients with advanced CKD. Data of 121 Japanese patients with CKD who were newly administered 10 mg dapagliflozin in our department between August 2021 and August 2022 were analyzed. Changes in UA and fractional excretion of UA (FEUA) were analyzed using multiple regression analysis. Of 75 patients, 21 (28.0%) patients, 24 (32.0%) patients, 29 (38.7%) patients, and 1 (1.3%) patient were categorized as having CKD stage 3a, 3b, 4, and 5, respectively. The median age was 67 years, and 72.0% were male. 23 (30.7%) of patients had diabetes mellitus. The median estimated glomerular filtration rate, serum UA, and FEUA were 35.7 mL/min/1.73 m2, 6.4 mg/dL, and 6.76%, respectively, at the time of dapagliflozin administration. After administration, serum UA decreased to 5.6 mg/dL and FEUA increased to 9.22%. Dapagliflozin increases FEUA and reduces serum UA levels in patients with advanced CKD. |
| first_indexed | 2024-04-09T21:38:13Z |
| format | Article |
| id | doaj.art-a67b8886f4824e2896dedc577ebab124 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-04-09T21:38:13Z |
| publishDate | 2023-03-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-a67b8886f4824e2896dedc577ebab1242023-03-26T11:11:15ZengNature PortfolioScientific Reports2045-23222023-03-011311710.1038/s41598-023-32072-yThe effect of dapagliflozin on uric acid excretion and serum uric acid level in advanced CKDYukimasa Iwata0Shoki Notsu1Yushi Kawamura2Waka Mitani3Shinjiro Tamai4Madoka Morimoto5Masafumi Yamato6Department of Nephrology, Sakai City Medical CenterDepartment of Nephrology, Sakai City Medical CenterDepartment of Nephrology, Sakai City Medical CenterDepartment of Nephrology, Sakai City Medical CenterDepartment of Nephrology, Sakai City Medical CenterDepartment of Nephrology, Sakai City Medical CenterDepartment of Nephrology, Sakai City Medical CenterAbstract Sodium–glucose cotransporter 2 inhibitors (SGLT2i) exhibit renoprotective effect in patients with chronic kidney disease (CKD) and reduce serum uric acid (UA) in patients with diabetes mellitus. However, it is not clarified whether SGLT2i reduce serum UA levels in patients with advanced CKD. This study aimed to investigate the impact of SGLT2i on change in serum UA levels in patients with advanced CKD. Data of 121 Japanese patients with CKD who were newly administered 10 mg dapagliflozin in our department between August 2021 and August 2022 were analyzed. Changes in UA and fractional excretion of UA (FEUA) were analyzed using multiple regression analysis. Of 75 patients, 21 (28.0%) patients, 24 (32.0%) patients, 29 (38.7%) patients, and 1 (1.3%) patient were categorized as having CKD stage 3a, 3b, 4, and 5, respectively. The median age was 67 years, and 72.0% were male. 23 (30.7%) of patients had diabetes mellitus. The median estimated glomerular filtration rate, serum UA, and FEUA were 35.7 mL/min/1.73 m2, 6.4 mg/dL, and 6.76%, respectively, at the time of dapagliflozin administration. After administration, serum UA decreased to 5.6 mg/dL and FEUA increased to 9.22%. Dapagliflozin increases FEUA and reduces serum UA levels in patients with advanced CKD.https://doi.org/10.1038/s41598-023-32072-y |
| spellingShingle | Yukimasa Iwata Shoki Notsu Yushi Kawamura Waka Mitani Shinjiro Tamai Madoka Morimoto Masafumi Yamato The effect of dapagliflozin on uric acid excretion and serum uric acid level in advanced CKD Scientific Reports |
| title | The effect of dapagliflozin on uric acid excretion and serum uric acid level in advanced CKD |
| title_full | The effect of dapagliflozin on uric acid excretion and serum uric acid level in advanced CKD |
| title_fullStr | The effect of dapagliflozin on uric acid excretion and serum uric acid level in advanced CKD |
| title_full_unstemmed | The effect of dapagliflozin on uric acid excretion and serum uric acid level in advanced CKD |
| title_short | The effect of dapagliflozin on uric acid excretion and serum uric acid level in advanced CKD |
| title_sort | effect of dapagliflozin on uric acid excretion and serum uric acid level in advanced ckd |
| url | https://doi.org/10.1038/s41598-023-32072-y |
| work_keys_str_mv | AT yukimasaiwata theeffectofdapagliflozinonuricacidexcretionandserumuricacidlevelinadvancedckd AT shokinotsu theeffectofdapagliflozinonuricacidexcretionandserumuricacidlevelinadvancedckd AT yushikawamura theeffectofdapagliflozinonuricacidexcretionandserumuricacidlevelinadvancedckd AT wakamitani theeffectofdapagliflozinonuricacidexcretionandserumuricacidlevelinadvancedckd AT shinjirotamai theeffectofdapagliflozinonuricacidexcretionandserumuricacidlevelinadvancedckd AT madokamorimoto theeffectofdapagliflozinonuricacidexcretionandserumuricacidlevelinadvancedckd AT masafumiyamato theeffectofdapagliflozinonuricacidexcretionandserumuricacidlevelinadvancedckd AT yukimasaiwata effectofdapagliflozinonuricacidexcretionandserumuricacidlevelinadvancedckd AT shokinotsu effectofdapagliflozinonuricacidexcretionandserumuricacidlevelinadvancedckd AT yushikawamura effectofdapagliflozinonuricacidexcretionandserumuricacidlevelinadvancedckd AT wakamitani effectofdapagliflozinonuricacidexcretionandserumuricacidlevelinadvancedckd AT shinjirotamai effectofdapagliflozinonuricacidexcretionandserumuricacidlevelinadvancedckd AT madokamorimoto effectofdapagliflozinonuricacidexcretionandserumuricacidlevelinadvancedckd AT masafumiyamato effectofdapagliflozinonuricacidexcretionandserumuricacidlevelinadvancedckd |